ArticleBriefings in bioinformatics2026
Confidence scoring for deep learning-predicted antibody-antigen complexes: AntiConf as a precision-driven metric.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DeepRank-Ab: a scoring function for antibody-antigen complexes based on geometric deep learning.Communications biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate determination of antibody-antigen (Ab-Ag) complex structures is critical for therapeutic development. While deep learning-based methods, beginning with AlphaFold2 (AF2), have revolutionized multimer predictions, the optimal strategies for Ab-Ag modeling, and the reliability of their confidence scores remain active areas of research. This study evaluates the performance of AF2, Boltz-1, Boltz-1x, Boltz-2, Chai-1, Protenix, Protenix-1, OpenFold3, and ESMFold, on a curated dataset of 200 Ab-Ag complexes. Among the nine methods tested, Protenix-1 emerged as the top performer, with Chai-1 consistently ranking second across multiple success metrics, closely followed by AF2. We observed diverse effects of recycling iterations, with AF2, Chai-1, and Protenix variants benefiting from increased cycles, unlike Boltz variants. We analyzed various model confidence scores, noting high precision from pDockQ2 and high recall from predicted Template-Modeling (pTM) score. By integrating these two scores, we developed antibody confidence (AntiConf), a novel metric that achieves superior performance for all methods in terms of precision and recall. These strengths make AntiConf a valuable post score for both computational predictions and downstream experimental workflows, reflecting its potential to improve Ab-Ag complex predictions by AF2 and AF3 architectures. Altogether, this study addresses current limitations in deep learning-based Ab-Ag complex prediction, showcasing the potential of AntiConf for future assessment studies, and providing a guideline for improving the accuracy of Ab-Ag complex prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.